[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610136":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":144,"collaborators":25,"id":146,"slug":25,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":25,"eligibilityCriteria":151,"healthyVolunteers":147,"sex":152,"minAge":153,"maxAge":25,"enrollmentInfo":154,"targetDuration":25,"studyType":157,"phases":158,"briefSummary":161,"conditions":162,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Arrowhead Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ARO-DIMERPA","EXPERIMENTAL","ARO-DIMERPA in single or multiple ascending doses",[13],"Drug: ARO-DIMERPA",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (normal saline, 0.9%) in single or multiple matching doses",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Subcutaneous (SC) injection",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Calculated volume to match active treatment by SC injection",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Medical Monitor","CONTACT","626-304-3400","ARODIMERPA-1001@arrowheadpharma.com",[36,50,60,70,79,89,98,109,121,129,135],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":25},"Research Site 7","RECRUITING","Charlestown","New South Wales","2290","Australia","AU",{"type":45,"coordinates":46},"Point",[47,48],151.69318,-32.96828,{"lat":48,"lon":47},{"facility":51,"status":38,"city":52,"state":53,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":25},"Research Site 5","Morayfield","Queensland","4506",{"type":45,"coordinates":56},[57,58],152.94907,-27.10876,{"lat":58,"lon":57},{"facility":61,"status":38,"city":62,"state":63,"zip":64,"country":42,"countryCode":43,"cosmosGeoPoint":65,"geoPoint":69,"contacts":25},"Research Site 8","East Melbourne","Victoria","3002",{"type":45,"coordinates":66},[67,68],144.9879,-37.81667,{"lat":68,"lon":67},{"facility":71,"status":38,"city":72,"state":63,"zip":73,"country":42,"countryCode":43,"cosmosGeoPoint":74,"geoPoint":78,"contacts":25},"Research Site 4","Melbourne","3153",{"type":45,"coordinates":75},[76,77],144.96332,-37.814,{"lat":77,"lon":76},{"facility":80,"status":38,"city":81,"state":82,"zip":83,"country":42,"countryCode":43,"cosmosGeoPoint":84,"geoPoint":88,"contacts":25},"Research Site 9","Perth","Western Australia","6009",{"type":45,"coordinates":85},[86,87],115.8614,-31.95224,{"lat":87,"lon":86},{"facility":90,"status":38,"city":91,"state":25,"zip":92,"country":42,"countryCode":43,"cosmosGeoPoint":93,"geoPoint":97,"contacts":25},"Research Site 11","Clayton","3168",{"type":45,"coordinates":94},[95,96],145.11667,-37.91667,{"lat":96,"lon":95},{"facility":99,"status":38,"city":100,"state":25,"zip":101,"country":102,"countryCode":103,"cosmosGeoPoint":104,"geoPoint":108,"contacts":25},"Research Site 10","Calgary","T2N 4N1","Canada","CA",{"type":45,"coordinates":105},[106,107],-114.08529,51.05011,{"lat":107,"lon":106},{"facility":110,"status":38,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":25},"Research Site 6","Grafton","Auckland","1023","New Zealand","NZ",{"type":45,"coordinates":117},[118,119],174.76566,-36.86029,{"lat":119,"lon":118},{"facility":122,"status":38,"city":112,"state":25,"zip":123,"country":114,"countryCode":115,"cosmosGeoPoint":124,"geoPoint":128,"contacts":25},"Research Site 3","2025",{"type":45,"coordinates":125},[126,127],174.76349,-36.84853,{"lat":127,"lon":126},{"facility":130,"status":38,"city":112,"state":25,"zip":131,"country":114,"countryCode":115,"cosmosGeoPoint":132,"geoPoint":134,"contacts":25},"Research Site 2","622",{"type":45,"coordinates":133},[126,127],{"lat":127,"lon":126},{"facility":136,"status":38,"city":137,"state":25,"zip":138,"country":114,"countryCode":115,"cosmosGeoPoint":139,"geoPoint":143,"contacts":25},"Research Site 1","Christchurch","8011",{"type":45,"coordinates":140},[141,142],172.63333,-43.53333,{"lat":142,"lon":141},{"type":145,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100610136",false,"NCT07223658","Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia","Phase 1\u002F2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia","Inclusion Criteria:\n\n* Willing to follow diet counseling as per Investigator judgment based on local standard of care\n* Specific fasting TG, LDL-C, and non-high density lipoprotein cholesterol levels at Screening\n* Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later; participants must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later\n\nExclusion Criteria:\n\n* Current use or use within last 365 days or within 5-half-lives before Day 1 based on plasma PK, whichever is longer, of any hepatocyte-targeted siRNA\n* Current use or use within last 90 days or within 5-half-lives before Day 1 based on plasma PK, whichever is longer, of any antisense oligonucleotide therapy\n* Current use or use within last 60 days from Day 1 of any PCSK9 inhibitor monoclonal antibodies (eg, evolocumab or alirocumab)\n* Uncontrolled hypertension\n* History of bleeding diathesis or coagulopathy\n* Current diagnosis of nephrotic syndrome\n\nNote: Additional inclusion\u002Fexclusion criteria may apply per protocol.","ALL","18 Years",{"count":155,"type":156},78,"ESTIMATED","INTERVENTIONAL",[159,160],"PHASE1","PHASE2","Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.",[163],"Hyperlipidemia; Mixed","2026-06-29",{"date":166,"type":167},"2026-06-30","ACTUAL",{"date":169,"type":167},"2025-12-22",{"date":171,"type":156},"2027-07",{"name":5,"class":6},11]